Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Fractional heat shock protein 27 urine excretion as a short-term predictor in acute exacerbation of chronic obstructive pulmonary disease
Authors:Traxler, Denise (Author)
Zimmermann, Matthias (Author)
Simader, Elisabeth (Author)
Einwallner, Elisa (Author)
Copic, Dragan (Author)
Graf, Alexandra (Author)
Mueller, Thomas (Author)
Veraar, Cecilia (Author)
Lainščak, Mitja (Author)
Marčun, Robert (Author)
Košnik, Mitja (Author)
Fležar, Matjaž (Author)
Rozman, Aleš (Author)
Korošec, Peter (Author)
Language:English
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and is characterized by episodes of acute exacerbations. Finding a systemic biomarker that reliably predicts outcome after an acute exacerbation remains a major challenge. Heat shock protein 27 (HSP27) has been previously studied in COPD, however, urine excretion trajectory and prognostic value after an exacerbation is unknown. Methods: In this retrospective post hoc analysis of a prospective study that included 253 COPD patients who were hospitalized for acute exacerbation, 207 patients were analyzed. Urine and serum were sampled at admission, discharge, and 180 days after discharge; urine excretion trajectory was analyzed and correlated with clinicopathological and survival data. Results: HSP27 urine excretion increased after an exacerbation episode [1.8% admission, 1.8% discharge, 2.3% 180 days after discharge (P=0.091)]. In severely ill patients (GOLD IV) this course was even more distinct [1.6% admission, 2.1% discharge, 2.8% 180 days after discharge (P=0.007)]. Furthermore, fractional HSP27 urine excretion at discharge was increased in GOLD IV patients (P=0.031). In Kaplan-Meier and univariable Cox proportional hazard models patients with HSP27 urine excretion below 0.845% showed significantly worse survival at 30, 90 and 180 days after discharge. In a multivariable Cox proportional hazard model including established COPD outcome parameters fractional HSP27 urine excretion remained a significant predictor of survival at 30 and 90 days after discharge. Comparing this model to our already published model that includes HSP27 serum concentration we could show that fractional HSP27 urine excretion performs better in short-term survival. Conclusions: Our findings provide novel information about fractional HSP27 urine excretion trajectory in acute exacerbation of COPD. Fractional HSP27 urine excretion may be significantly reduced during an episode of acute exacerbation in COPD patients and may be used as a predictor of short-term all-cause mortality.
Keywords:biomarkers, heat-shock proteins, chronic obstructive pulmonary disease, urine, heat shock protein 27
Year of publishing:2020
Publisher:AME Publishing Company
Source:Kitajska
COBISS_ID:47394051 Link is opened in a new window
UDC:616.2
ISSN on article:2305-5847
OceCobissID:33574617 Link is opened in a new window
DOI:10.21037/atm-20-3683 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Soavtorji iz Slovenije: Mitja Lainscak, Robert Marčun, Mitja Košnik, Matjaž Fležar, Aleš Rozman, Peter Korošec; Opis vira z dne 18. 1. 2021;
Views:190
Downloads:61
Files:.pdf PDF - Presentation file, download (691,92 KB)
URL URL - Source URL, visit https://atm.amegroups.com/article/view/59820/pdf
 
Journal:Ann. transl. med.
AME Publishing Company
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© Annals of Translational Medicine
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:30.09.2020

Back